Effect of hyperlipidemia on prognosis of the patients with hepatitis B related hepatocellular carcinoma

doi:10.16139/j.1007-9610.2024.02.09

Abstract

Abstract:

Objective To explore the effect of hyperlipidemia and lipid-lowering therapy on the prognosis of postoperative patients with hepatitis B related hepatocellular carcinoma. Methods The clinical data of the patients with hepatitis B related hepatocellular carcinoma who were operated in our hospital from January 2012 to January 2021 were retrospectively collected. The effect of blood lipid level and related lipid-lowering therapy on the prognosis of postoperative patients with hepatitis B related hepatocellular carcinoma was analyzed. Results Among 166 patients with hepatitis B related hepatocellular carcinoma, there were 63 cases had hyperlipidemia, of which 33 cases were treated by statins. The median postoperative disease free survival time in the hyperlipidemia group was significantly lower than that in the normal blood lipid group (24.8 months vs. 38.5 months, P<0.05), and the median overall survival time in the hyperlipidemia group was also significantly lower than that in the normal blood lipid group (30.1 months vs. 44.5 months, P<0.05). There was no statistically significant difference in prognosis between the patients with hyperlipidemia who used statins or not. The median disease free survival time was 23.4 months vs. 26.3 months, and the median overall survival time was 29.7 months vs. 30.3 months. Conclusions Hyperlipidemia is a risk factor for disease free survival and overall survival after surgery in the patients with hepatitis B related hepatocellular carcinoma. The use of statins alone in hyperlipidemia patients cannot reduce the risk of recurrence and prolong survival time.

Key words: Hyperlipidemia, Hepatocellular carcinoma, Hepatitis B related, Lipid-lowering treatment, Statin, Prognosis

CLC Number:

SONG Qingjie, TANG Juanjuan, ZHAO Jianquan, SONG hui, YANG Jun. Effect of hyperlipidemia on prognosis of the patients with hepatitis B related hepatocellular carcinoma[J]. Journal of Surgery Concepts & Practice, 2024, 29(02): 143-147.

Figures/Tables 5

Tab 1

Tab 2

Tab 3

Fig 1

Fig 2

References 20

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2]	DE MARTEL C, MAUCORT-BOULCH D, PLUMMER M, et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma[J]. Hepatology, 2015, 62(4):1190-1200. doi: 10.1002/hep.27969 pmid: 26146815
[3]	LIU J, ZHANG S K, WANG Q M, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based,cross-sectional study[J]. Lancet Infect Dis, 2016, 16(1):80-86.
[4]	黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(2):113-118.
	HUANG J W, QIU G T, ZENG Y. Advances in the surgical treatment of hepatocellular carcinoma[J]. J Surg Concepts Pract, 2022, 27(2):113-118.
[5]	PHAN J, NG V, SHEINBAUM A, et al. Hyperlipidemia and nonalcoholic steatohepatitis predispose to hepatocellular carcinoma development without cirrhosis[J]. J Clin Gastroenterol, 2019, 53(4):309-313. doi: 10.1097/MCG.0000000000001062 pmid: 29912756
[6]	PAUL B, LEWINSKA M, ANDERSEN J B. Lipid alterations in chronic liver disease and liver cancer[J]. JHEP Rep, 2022, 4(6):100479.
[7]	由金玲, 徐晓慧, 林琳, 等. 基于GBD数据分析1990年和2019年中国人群癌谱差异[J]. 中国肿瘤, 2024, 33(1):36-43.
	YOU J L, XU X H, LIN L, et al. Analysis of cancer spectrum in China based on GBD data in 1990 and 2019[J]. China Cancer, 2024, 33(1):36-43.
[8]	GONG F, YANG N L, WANG X W, et al. Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics[J]. Nano Today, 2020,32:100851
[9]	ZHENG J, GAO P. Toward normalization of the tumor microenvironment for cancer therapy[J]. Integr Cancer Ther, 2019,18:1534735419862352.
[10]	PORPORATO P E, PAYEN V L, DE SAEDELEER C J, et al. Lactate stimulates angiogenesis and accelerates the healing of superficial and ischemic wounds in mice[J]. Angiogenesis, 2012, 15(4):581-592. doi: 10.1007/s10456-012-9282-0 pmid: 22660894
[11]	SUNDELIN J P, LIDBERG U, NIK A M, et al. Hypoxia-induced regulation of the very low density lipoprotein receptor[J]. Biochem Biophys Res Commun, 2013, 437(2):274-279.
[12]	VERNIERI C, CASOLA S, FOIANI M, et al. Targeting cancer metabolism: dietary and pharmacologic interventions[J]. Cancer Discov, 2016, 6(12):1315-1333. pmid: 27872127
[13]	STOPSACK K H, GERKE T A, SINNOTT J A, et al. Cholesterol metabolism and prostate cancer lethality[J]. Cancer Res, 2016, 76(16):4785-4790. doi: 10.1158/0008-5472.CAN-16-0903 pmid: 27325648
[14]	LYU J, YANG E J, HEAD S A, et al. Astemizole inhibits mTOR signaling and angiogenesis by blocking cholesterol trafficking[J]. Int J Biol Sci, 2018, 14(10):1175-1185. doi: 10.7150/ijbs.26011 pmid: 30123067
[15]	LYU J, YANG E J, HEAD S A, et al. Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth[J]. Cancer Lett, 2017,409:91-103.
[16]	WOOD F A, HOWARD J P, FINEGOLD J A, et al. N-of-1 trial of a statin, placebo,or no treatment to assess side effects[J]. N Engl J Med, 2020, 383(22):2182-2184.
[17]	YANG F, KOU J, LIU Z, et al. MYC enhances cholesterol biosynthesis and supports cell proliferation through SQLE[J]. Front Cell Dev Biol, 2021,9:655889.
[18]	LEBEAU P F, BYUN J H, PLATKO K, et al. Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance[J]. Nat Commun, 2022, 13(1):770. doi: 10.1038/s41467-022-28240-9 pmid: 35140212
[19]	CHEN J, DING C, CHEN Y, et al. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway[J]. Cancer Lett, 2021, 502:154-165.
[20]	ZHANG F, GAO J, LIU X, et al. LATS‐regulated nuclear‐cytoplasmic translocation of SREBP2 inhibits hepatocellular carcinoma cell migration and invasion via epithelial-mesenchymal transition[J]. Mol Carcinog, 2023, 62(7):963-974.

Clinical pathological characteristics	Hyperlipidemia
Clinical pathological characteristics	Total	No	Yes	χ²value	P value
Age (years)				0.094	0.759
≤50	22	13(59.1)	9(40.9)
>50	144	90(62.5)	54(37.5)
Gender				0.889	0.346
Man	114	68(59.6)	46(40.4)
Woman	52	35(67.3)	17(32.4)
Tumor diameter（cm）				0.019	0.889
≤5	99	61(61.6)	38(38.4)
>5	67	42(62.7)	25(37.3)
Microvascular cancer thrombus				2.371	0.124
Yes	59	32(54.2)	27(45.8)
No	107	71(66.4)	36(33.6)
TNM stage				0.989	0.320
Ⅰ	69	43(62.3)	26(37.7)
Ⅱ+Ⅲ	97	60(61.9)	37(38.1)

Item	Hyperlipidemia group (n=63)	Normal blood lipid group (n=103)	χ²/t value	P value
Accumulated 1-year survival rate	61(96.8)	103(100)
Accumulated 3-year survival rate	47(74.6)	83(80.6)	750	0.000
Accumulated 5-year survival rate	28（44.4）	53（51.5）
OS (months)	30.1±11.9	44.5±15.6	-6.708	0.000

Item	Hyperlipidemia group (n=63)	Normal blood lipid group (n=103)	χ²/t value	P value
Accumulated 1-year recurrence rate	16(25.4)	11(10.7)
Accumulated 3-year recurrence rate	35(55.6)	53(51.5)	452	0.000
Accumulated 5-year recurrence rate	45（71.4）	66（64.1）
DFS (months)	24.8±10.9	38.5±18.5	-5.335	0.000